Teva Pharmaceutical Industries (TEVA) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $36.58. The rating moved from Overbought to Neutral on August 19, 2026.

• Public ratingNeutral (as of August 19, 2026)
• Last close$36.58
• Last changeMoved from Overbought to Neutral on August 19, 2026
• SectorHealthcare
• IndustryDrug Manufacturers - Specialty & Generic

AI analysis

Teva Pharmaceutical Industries (TEVA) combines a leading global generics platform with specialty assets that together produce steady cash flow. Recent operational efficiencies and explicit debt-reduction actions support improving financial flexibility, while biosimilar/specialty initiatives provide incremental growth optionality. Headwinds include persistent payer-driven pricing pressure, leverage-related sensitivity to rates, and legacy legal/operational risks that could weigh on performance if cash generation weakens. Near-term catalysts include margin improvements from cost programs, favorable generics tender outcomes, and any positive developments in specialty programs, while continued payer consolidation and litigation outcomes are primary downside risks.

Key factors

• Scale in global generics provides a diversified, stable cash-flow base and pricing leverage in many markets
• Ongoing cost-cutting and restructuring initiatives are improving margins and free cash flow generation
• Specialty franchises and biologics/biosimilar initiatives offer mid-term upside beyond generics (CNS, migraine/neurology exposure)
• Management focus on debt reduction and portfolio optimization reduces financial vulnerability over time
• Macro/regulatory tailwinds (expanded access policies) could support volume in relevant therapeutic classes

Risks

• Sustained pricing pressure from payers, PBMs and strategic rationalization that compresses generics margins
• High leverage and interest-rate sensitivity create refinancing and liquidity risk if cash generation falters
• Ongoing litigation and legacy legal exposures that could require cash outflows or settlements
• Competition, patent expirations and faster-than-expected generic erosion in key specialty products
• Operational and supply-chain disruptions or manufacturing quality issues that impact revenue or lead to recalls

Latest MarketMoodz coverage

• Axsome Nets Global Rights to Takeda's Balipodect, Expands Schizophrenia Pipeline2026-04-01
• Goldman Sachs names Nvidia among five compelling buys2026-02-14

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.